Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

11.07.2022 | comment

Breast implant-associated anaplastic large-cell lymphoma—update on challenges, advances and opportunities

verfasst von: Andreas Pircher, MD PhD, Roberto N. Miranda

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Auszug

In this issue of MEMO, Ghindinelli et al. [1] report on a rare case of breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) including a review of the literature. The authors report on an interesting case of a patient with several breast reconstructive operations following thoracic trauma including implantation of breast implants, which led to development of a BIA-ALCL and, finally, successful surgical removal. Although the case report leaves several questions on current recommendations for management, it highlights the multidisciplinary management of the disease starting from diagnostic work-up until standard follow-up visits. …
Vorheriger Artikel Breast implant-associated anaplastic large-cell lymphoma: a European case report and literature review
Nächster Artikel Essential news and practice changing trials in oesophageal, gastroesophageal junction and gastric cancer in 2021
Literatur
1.
2.
Clemens MW, Jacobsen ED, Horwitz SM. 2019 NCCN consensus guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Aesthet Surg J. 2019;39(Suppl_1):S3–S13.CrossRef
3.
Nelson JA, McCarthy C, Dabic S, Polanco T, Chilov M, Mehrara BJ, et al. BIA-ALCL and textured breast implants: a systematic review of evidence supporting surgical risk management strategies. Plast Reconstr Surg. 2021;147(5S):7S–13S.CrossRef
4.
Wang Y, Zhang Q, Tan Y, Lv W, Zhao C, Xiong M, et al. Current progress in breast implant-associated anaplastic large cell lymphoma. Front Oncol. 2021;11:785887.CrossRef
5.
Ferrufino-Schmidt MC, Medeiros LJ, Liu H, Clemens MW, Hunt KK, Laurent C, et al. Clinicopathologic features and prognostic impact of lymph node involvement in patients with breast implant-associated anaplastic large cell lymphoma. Am J Surg Pathol. 2018;42(3):293–305.CrossRef
6.
Walker JN, Hanson BM, Pinkner CL, Simar SR, Pinkner JS, Parikh R, et al. Insights into the microbiome of breast implants and Periprosthetic tissue in breast implant-associated anaplastic large cell lymphoma. Sci Rep. 2019;9(1):10393.CrossRef
7.
DeCoster RC, Lynch EB, Bonaroti AR, Webster JM, Butterfield TA, Evers BM, et al. Breast implant-associated anaplastic large cell lymphoma: an evidence-based systematic review. Ann Surg. 2021;273(3):449–58.CrossRef
Metadaten
Titel
Breast implant-associated anaplastic large-cell lymphoma—update on challenges, advances and opportunities
verfasst von
Andreas Pircher, MD PhD
Roberto N. Miranda
Publikationsdatum
11.07.2022
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00821-w

Weitere Artikel der Ausgabe 3/2022

Systemic inflammatory response index is a prognostic biomarker in unresectable pancreatic adenocarcinoma and identifies patients for more intensive treatment

  • original report

Publisher Correction: Brain metastases: new systemic treatment approaches

  • Open Access
  • Publisher Correction

CAR-T cells—Real-time experience applying CAR-T cells—What we have learned so far

  • editorial

Real time experience applying CAR T-cells for B-cell lymphoma—What we have learned so far: Acute toxicity management

  • short review

Neoadjuvant treatment for solid tumors—the earlier, the better

  • editorial

Molecular profiling leading to personalized treatment in breast cancer

  • Open Access
  • short review